Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Robert Clarke Stories

2012-07-02 21:42:17

Researchers at Georgetown Lombardi Comprehensive Cancer Center have uncovered a single molecule they say is a major determinant of resistance to anti-estrogen therapy used to treat or prevent breast cancer in high-risk women. In the July 1 issue of Cancer Research, the scientists say glucose-regulated protein 78 (GRP78), activated as breast cells undergo stress induced by the agents tamoxifen and fulvestrant, turns off apoptosis, a cell death response, and turns on autophagy. In autophagy,...

2011-06-16 13:08:18

The first roadmap to mathematical modeling of a powerful basic "decision circuit" in breast cancer has been developed and published in Nature Reviews Cancer. The preliminary mathematical model is the first result of a $7.5 million federal grant, awarded to scientists at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) and collaborators at Virginia Tech and Fox Chase Cancer Center, to develop a systems approach to understanding and treating one of the...

2010-05-10 08:53:19

A study by researchers from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown University Medical Center (GUMC) identifies a potential new combination therapy to "rescue" treatment sensitivity to fulvestrant in estrogen receptor positive breast cancers. The findings are published May 15, 2010 as the cover story of Molecular Cancer Therapeutics. Fulvestrant is a common second-line therapy for women whose cancer progresses following anti-estrogen therapy. In this paper, Lombardi...

439c61d1b9bb9a5a3c85ae883e0c24051
2010-02-16 10:19:08

Chemical found in feverfew, long a staple of natural herbal medicine, shuts down pro-survival signal in resistant breast cancer cells Combining tamoxifen, the world's most prescribed breast cancer agent, with a compound found in the flowering plant feverfew may prevent initial or future resistance to the drug, say researchers at Georgetown Lombardi Comprehensive Cancer Center. The finding, reported online Feb. 12 in FASEB, provides new insight into the biological roots of that resistance, and...

2010-01-06 11:46:18

Researchers find out why estrogen-positive tumors stop responding to commonly used drugs, pointing a way to new therapies Researchers at Georgetown Lombardi Comprehensive Cancer Center have found a way to cleverly override signals that tell breast cancer cells to keep surviving in the face of anticancer treatment. The investigational agent they used renews the sensitivity of these breast cancer cells to treatment by fulvestrant (Faslodex®) which had stopped working. They add...